Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder. Maillart E, Dubessy AL, Shor N, Piljan M, et al. Neurology 2025;104:e213399.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Maillart E, Dubessy AL, Shor N, Piljan M, et al. Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder. Neurology 2025;104:e213399.
PMID: 39913883